Neuphoria Therapeutics (NEUP) Receivables - Other (2020 - 2026)
Neuphoria Therapeutics (NEUP) reported Receivables - Other of $807945.0 for Q1 2026, up 27683.53% year-over-year from N/an in Q1 2025, and up 65.44% on a QoQ basis from $488372.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 7 years of Receivables - Other data on file, last reported at $807945.0 in Q1 2026.
- Quarterly Receivables - Other rose 27683.53% year-over-year to $807945.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $807945.0 (up 27683.53% YoY) and the FY2024 annual result came in at $96154.0, up 37314.01% from the prior year.
- Receivables - Other advanced to $807945.0 in Q1 2026 per NEUP's latest filing, from $488372.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $807945.0 in Q1 2026 and bottomed at $592.17 in Q2 2023.
- The 5-year median for Receivables - Other is $30429.2 (2022), against an average of $170089.4.
- The widest annual swing landed in 2025, when Receivables - Other tumbled 98.25%; it then jumped 27683.53% in 2026.
- Tracing NEUP's Receivables - Other over 5 years: stood at $30429.2 in 2022, then tumbled by 98.05% to $592.17 in 2023, then soared by 241.29% to $2021.0 in 2024, then surged by 24064.87% to $488372.0 in 2025, then surged by 65.44% to $807945.0 in 2026.
- Per Business Quant, the three latest NEUP Receivables - Other figures stand at $807945.0 (Q1 2026), $488372.0 (Q4 2025), and $1758.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 807,945.00 |
| Mar 31, 2026 | 807,945.00 |
| Dec 31, 2025 | 488,372.00 |
| Dec 31, 2025 | 488,372.00 |
| Sep 30, 2025 | 1,758.00 |
| Sep 30, 2025 | 1,758.00 |
| Jun 30, 2025 | 237.00 |
| Jun 30, 2025 | 237.00 |
| Mar 31, 2025 | 2,908.00 |
| Mar 31, 2025 | 2,908.00 |
| Dec 31, 2024 | 2,021.00 |
| Dec 31, 2024 | 2,021.00 |
| Sep 30, 2024 | 1,276.00 |
| Sep 30, 2024 | 1,276.00 |
| Jun 30, 2024 | 96,154.00 |
| Jun 30, 2024 | 96,154.00 |
| Jun 30, 2023 | 419,435.61 |
| Jun 30, 2023 | 419,435.61 |
| Jun 30, 2022 | 30,429.23 |
| Jun 30, 2022 | 30,429.23 |
| Dec 31, 2021 | 799,485.85 |
| Dec 31, 2021 | 799,485.85 |
| Jun 30, 2021 | 148,532.09 |
| Jun 30, 2021 | 148,532.09 |
| Jun 30, 2020 | 504,709.28 |
| Jun 30, 2020 | 504,709.28 |